Bionano Genomics (BNGO) director awarded 9,149 stock options vesting over 12 months
Bionano Genomics director Kristiina Vuori, MD, was granted 9,149 stock options at an exercise price of $1.19 per share. These options, part of her compensation, will vest in equal monthly installments over 12 months or fully upon a Change of Control, and expire on May 13, 2036. This transaction is considered a neutral event in terms of filing impact and sentiment, as it represents equity compensation rather than an open-market purchase.
MAY 14·www.sharewise.com→
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).
APR 30·The Globe and Mail→
Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026
Bionano Genomics, Inc. (Nasdaq: BNGO) announced it will report its first quarter 2026 financial results and discuss recent corporate progress during a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time. Interested parties can register for the event and a replay will be available on the company's investor relations website for at least 30 days.
